

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Docket No.: DEX0478US.NP
Inventors: Wolfert et al.
Serial No.: 10/552,084
Filing Date: December 1, 2006
Examiner: Niebauer, Ronald T.
Customer No.: 32800
Group Art Unit: 1654
Confirmation No.: 4146
Title: New Uses of Lp-PLA2 in Combination
to Assess Coronary Risk

Electronically Submitted via EFS-Web
Date: April 17, 2009

I hereby certify that this paper is being electronically
submitted on the date indicated above to the
Commissioner for Patents, U.S. Patent &
Trademark Office.

By 
Typed Name: Kathleen A. Tyrrell, Reg. No. 38,350

Commissioner for Patents
U.S. Patent & Trademark Office

Dear Sir:

Reply with Request for Continued Examination

This reply is responsive to the Final Rejection mailed October 17, 2008 setting a three (3) month statutory period for response. A Petition for a three (3) month extension of time and the requisite fee are provided herewith. Also provided herewith is a request for continued examination and the requisite fee. Please enter the following amendments, remarks and Declaration by Dr. Robert Wolfert into the record.

Attorney Docket No.: **DEX0478US.NP**
Inventors: **Wolfert et al.**
Serial No.: **10/552,084**
Filing Date: **December 1, 2006**
Page 2

Amendments to the Specification begin at page 3.

The pending claims are reflected in the listing of claims which begins on page 4 of this paper.

Remarks begin on page 10.

Attorney Docket No.: DEX0478US.NP
Inventors: Wolfert et al.
Serial No.: 10/552,084
Filing Date: December 1, 2006
Page 3

Amendments to the Specification:

Please replace line 1 of page 33 with the following:

~~Table 4.10~~ Table 4.12

Please replace line 9 of page 33 with the following:

~~Table 4.11~~ Table 4.13

Please replace the paragraph beginning at line 4 of page 34 with the following:

Cox regression analysis was performed on a variety of subpopulations with traditional risk factors. Specifically, hypertension, diabetes and smoking were examined either alone or in combination. The results show that the highest Lp-PLA2 tertile conferred a dramatic increase in risk for the diabetic subpopulation in the LDL<130 group. See Figures 10 and 11 and ~~table 4.12 below~~ table 4.14.

Please replace line 10 of page 34 with the following:

~~Table 4.12~~ Table 4.14